CRISPR/Cas9 in iPSCs has been used to correct disease-causing mutations, as exemplified by turning the APOE4 allele into APOE3, which has been shown to cut down on AD-related phenotypes, tau protein phosphorylation and Aβ secretion included (Schmid et al., 2020). Here, MAPT is linked to Alzheimer disease.